{"id":49431,"date":"2022-10-10T16:01:43","date_gmt":"2022-10-10T14:01:43","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/plexision-completes-development-of-plexapr-a-rapid-blood-test-to-predict-transplant-rejection\/"},"modified":"2022-10-10T16:01:43","modified_gmt":"2022-10-10T14:01:43","slug":"plexision-completes-development-of-plexapr-a-rapid-blood-test-to-predict-transplant-rejection","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/plexision-completes-development-of-plexapr-a-rapid-blood-test-to-predict-transplant-rejection\/","title":{"rendered":"Plexision completes development of PlexAPR\u2122, a rapid blood test to predict transplant rejection"},"content":{"rendered":"
\n

PITTSBURGH–(BUSINESS WIRE)–#healthcare<\/a>–Plexision, a biotechnology company, which provides personalized diagnostic testing services for organ transplant patients has completed development of a six-hour blood test to predict organ transplant rejection – PlexAPR\u2122. When combined with other clinical and laboratory information, rapid rejection-risk assessment can allow caregivers to intervene early, while arranging confirmatory biopsies, or during lifelong surveillance of organ health. To learn more, please visit https:\/\/plexision.com\/transplant-rejection\/plexapr<\/a>.\n<\/p>\n

<\/a><\/p>\n

\n\u201cTransplant rejection can happen at any time after transplantation and requires lifelong management of anti-rejection medications. Same-day delivery of test results is a valuable addition to personalized rejection-risk assessment and improving outcomes,\u201d said Rajeev Sindhi, CEO of Plexision.\n<\/p>\n

\nPlexAPR\u2122 is based on the presentation of donor antigen by circulating antigen presenting cells, such as B-cells. The test readout is a personalized index, only applicable to the patient being tested. Patient samples will be tested at the company\u2019s CLIA- and CAP-accredited reference laboratory in Pittsburgh.\n<\/p>\n

\nRoughly 40,000 patients receive solid organ transplants each year in the US. A limited number of drugs are available to prevent organ rejection. Rapid non-invasive surveillance of organ health provided by Plexision can improve survival and quality of life after transplantation.\n<\/p>\n

\nAbout Plexision:<\/b> Plexision\u2019s reference laboratory performs cell-based blood tests for personalized management of transplant rejection, infections in immunocompromised patients, and immune therapy in oncology. Transplant rejection testing services include the FDA-approved Pleximmune blood test to predict transplant rejection in children with liver or intestine transplants and the lab-developed Pleximark test to predict kidney transplant rejection. Tests that predict infection includes the lab-developed PlexCMV and the PlexCOVID-19 tests. These tests measure cell-mediated immunity to cytomegalovirus and the COVID-19 coronavirus, respectively. Plexision also performs custom R & D projects that require integration of cellular biomarker targets in all phases of development of drugs, vaccines, and gene therapy products, from pre-clinical to post-marketing. The company\u2019s portfolio of cell-based blood tests can be adapted to assess disease risk for several immunological disorders and develop personalized dosing recommendations. The company\u2019s reference laboratory in Pittsburgh, PA, is CLIA-approved, CAP-accredited and GMP-compliant. To learn more, visit www.plexision.com<\/a> or email info@plexision.com<\/a> or anupriya.saxena@plexision.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\ninfo@plexision.com<\/a>
or
\n
anupriya.saxena@plexision.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

PITTSBURGH–(BUSINESS WIRE)–#healthcare–Plexision, a biotechnology company, which provides personalized diagnostic testing services for organ transplant patients has completed development of a six-hour blood test to predict organ transplant rejection – PlexAPR\u2122. When combined with other clinical and laboratory information, rapid rejection-risk assessment can allow caregivers to intervene early, while arranging confirmatory biopsies, or during lifelong surveillance … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-49431","6":"format-standard","7":"category-industry"},"yoast_head":"\nPlexision completes development of PlexAPR\u2122, a rapid blood test to predict transplant rejection - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/plexision-completes-development-of-plexapr-a-rapid-blood-test-to-predict-transplant-rejection\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Plexision completes development of PlexAPR\u2122, a rapid blood test to predict transplant rejection - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"PITTSBURGH–(BUSINESS WIRE)–#healthcare–Plexision, a biotechnology company, which provides personalized diagnostic testing services for organ transplant patients has completed development of a six-hour blood test to predict organ transplant rejection – PlexAPR\u2122. When combined with other clinical and laboratory information, rapid rejection-risk assessment can allow caregivers to intervene early, while arranging confirmatory biopsies, or during lifelong surveillance ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/plexision-completes-development-of-plexapr-a-rapid-blood-test-to-predict-transplant-rejection\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-10T14:01:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221010005185\/en\/1596298\/21\/Plexision_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/plexision-completes-development-of-plexapr-a-rapid-blood-test-to-predict-transplant-rejection\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/plexision-completes-development-of-plexapr-a-rapid-blood-test-to-predict-transplant-rejection\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Plexision completes development of PlexAPR\u2122, a rapid blood test to predict transplant rejection\",\"datePublished\":\"2022-10-10T14:01:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/plexision-completes-development-of-plexapr-a-rapid-blood-test-to-predict-transplant-rejection\\\/\"},\"wordCount\":383,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/plexision-completes-development-of-plexapr-a-rapid-blood-test-to-predict-transplant-rejection\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221010005185\\\/en\\\/1596298\\\/21\\\/Plexision_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/plexision-completes-development-of-plexapr-a-rapid-blood-test-to-predict-transplant-rejection\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/plexision-completes-development-of-plexapr-a-rapid-blood-test-to-predict-transplant-rejection\\\/\",\"name\":\"Plexision completes development of PlexAPR\u2122, a rapid blood test to predict transplant rejection - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/plexision-completes-development-of-plexapr-a-rapid-blood-test-to-predict-transplant-rejection\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/plexision-completes-development-of-plexapr-a-rapid-blood-test-to-predict-transplant-rejection\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221010005185\\\/en\\\/1596298\\\/21\\\/Plexision_Logo.jpg\",\"datePublished\":\"2022-10-10T14:01:43+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/plexision-completes-development-of-plexapr-a-rapid-blood-test-to-predict-transplant-rejection\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/plexision-completes-development-of-plexapr-a-rapid-blood-test-to-predict-transplant-rejection\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/plexision-completes-development-of-plexapr-a-rapid-blood-test-to-predict-transplant-rejection\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221010005185\\\/en\\\/1596298\\\/21\\\/Plexision_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221010005185\\\/en\\\/1596298\\\/21\\\/Plexision_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/plexision-completes-development-of-plexapr-a-rapid-blood-test-to-predict-transplant-rejection\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Plexision completes development of PlexAPR\u2122, a rapid blood test to predict transplant rejection\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Plexision completes development of PlexAPR\u2122, a rapid blood test to predict transplant rejection - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/plexision-completes-development-of-plexapr-a-rapid-blood-test-to-predict-transplant-rejection\/","og_locale":"en_US","og_type":"article","og_title":"Plexision completes development of PlexAPR\u2122, a rapid blood test to predict transplant rejection - Pharma Trend","og_description":"PITTSBURGH–(BUSINESS WIRE)–#healthcare–Plexision, a biotechnology company, which provides personalized diagnostic testing services for organ transplant patients has completed development of a six-hour blood test to predict organ transplant rejection – PlexAPR\u2122. When combined with other clinical and laboratory information, rapid rejection-risk assessment can allow caregivers to intervene early, while arranging confirmatory biopsies, or during lifelong surveillance ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/plexision-completes-development-of-plexapr-a-rapid-blood-test-to-predict-transplant-rejection\/","og_site_name":"Pharma Trend","article_published_time":"2022-10-10T14:01:43+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221010005185\/en\/1596298\/21\/Plexision_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/plexision-completes-development-of-plexapr-a-rapid-blood-test-to-predict-transplant-rejection\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/plexision-completes-development-of-plexapr-a-rapid-blood-test-to-predict-transplant-rejection\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Plexision completes development of PlexAPR\u2122, a rapid blood test to predict transplant rejection","datePublished":"2022-10-10T14:01:43+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/plexision-completes-development-of-plexapr-a-rapid-blood-test-to-predict-transplant-rejection\/"},"wordCount":383,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/plexision-completes-development-of-plexapr-a-rapid-blood-test-to-predict-transplant-rejection\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221010005185\/en\/1596298\/21\/Plexision_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/plexision-completes-development-of-plexapr-a-rapid-blood-test-to-predict-transplant-rejection\/","url":"https:\/\/pharma-trend.com\/en\/plexision-completes-development-of-plexapr-a-rapid-blood-test-to-predict-transplant-rejection\/","name":"Plexision completes development of PlexAPR\u2122, a rapid blood test to predict transplant rejection - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/plexision-completes-development-of-plexapr-a-rapid-blood-test-to-predict-transplant-rejection\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/plexision-completes-development-of-plexapr-a-rapid-blood-test-to-predict-transplant-rejection\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221010005185\/en\/1596298\/21\/Plexision_Logo.jpg","datePublished":"2022-10-10T14:01:43+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/plexision-completes-development-of-plexapr-a-rapid-blood-test-to-predict-transplant-rejection\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/plexision-completes-development-of-plexapr-a-rapid-blood-test-to-predict-transplant-rejection\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/plexision-completes-development-of-plexapr-a-rapid-blood-test-to-predict-transplant-rejection\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221010005185\/en\/1596298\/21\/Plexision_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221010005185\/en\/1596298\/21\/Plexision_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/plexision-completes-development-of-plexapr-a-rapid-blood-test-to-predict-transplant-rejection\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Plexision completes development of PlexAPR\u2122, a rapid blood test to predict transplant rejection"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49431","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=49431"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49431\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=49431"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=49431"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=49431"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}